NASDAQ: QLGNQualigen Therapeutics Inc Stock
$3.58+0.10 (+2.87%)
Updated Apr 30, 2025
QLGN Price
$3.58
Fair Value Price
N/A
Market Cap
$2.64M
52 Week Low
$2.85
52 Week High
$29.44
P/E
-0.06x
P/B
-1.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.08
Operating Cash Flow
-$10M
Beta
0.7
Next Earnings
Jun 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
QLGN Overview
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QLGN's potential to beat the market
- QLGN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QLGN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important QLGN news, forecast changes, insider trades & much more!
QLGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QLGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QLGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
QLGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
QLGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more QLGN due diligence checks available for Premium users.
Valuation
QLGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-162.28x
Market
29.18x
QLGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.23x
Industry
4.45x
QLGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
QLGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.3M
Liabilities
$4.5M
Debt to equity
-2.08
QLGN's short-term liabilities ($4.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QLGN's short-term assets ($2.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QLGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QLGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$1.3M
Financing
$3.3M
QLGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QLGN vs Biotech Stocks
Qualigen Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.